Searching for more individual genes to predict responses to breast cancer therapy may not work, a new study suggests. Instead, scientists and clinicians need to pay attention to abnormalities in networks of genes, Yale researchers ...
Oct 21, 2016
0
2
University of Kentucky Markey Cancer Center Oncologist Dr. Edward Romond spent his career at UK treating and studying breast cancer, even leading major Phase 3 clinical trials on the breast cancer drug trastuzumab in the ...
Oct 13, 2016
0
31
A prominent physician scientist supported by the National Foundation of Cancer Research (NFCR), Dr. Daniel Haber, and his team at the Massachusetts General Hospital Cancer Center have identified a dynamic gene expression ...
Sep 6, 2016
0
2
A new measurement standard developed by the National Institute of Standards of Technology (NIST) has been used successfully by the Frederick National Laboratory for Cancer Research to check the performance of next-generation ...
Aug 17, 2016
0
4
Changes to HER2 testing guidelines for breast cancer in 2013 significantly increased the number of patients who test HER2-positive, according to a new study by Mayo Clinic researchers published in the Journal of Clinical ...
Jul 27, 2016
0
1
Cancer Research UK scientists have used imaging techniques as a new way to identify patients who could benefit from certain breast cancer treatments, according to a study published in Oncotarget.
Jul 8, 2016
0
0
(HealthDay)—An innovative set of clinical trials have identified two drugs that could provide a fighting chance for women with advanced breast cancer.
Jul 7, 2016
0
3
(HealthDay)—For women with advanced HER2-positive breast cancer, a similar but less expensive experimental drug works just as well as the standard drug Herceptin (trastuzumab), a new study finds.
Jun 3, 2016
0
47
A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer ...
Mar 14, 2016
0
93
A tumor's immune response to a single dose of the HER2 inhibitor trastuzumab predicted which patients with HER2-positive breast cancer would respond to the drug on a more long-term basis, according to the results of a study ...
Feb 29, 2016
0
6
